Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

Shanghai-based brain-computer interface (BCI) company StairMed, which claims to outperform Elon Musk’s Neuralink in certain ...

Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue growth, long-term margin expansion, and an ethos driving America’s health focus across ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast Eli Lilly ...

Eli Lilly has teamed up with insitro to develop ... a16z, GV and Third Rock Ventures. In May 2020 insitro raised $143m in a ...

Now, AH and Eli Lilly are rewriting the playbook with a ... Corporations prioritize consistent and growing cash flow and avoid high risk ventures. In contrast, VCs bet on future valuations and ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Gresham House Ventures commits €4.25m to Mobility Mojo, a dublin-based accessibility audit and data platform, to boost ...

Eli Lilly (NYSE: LLY) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in this morning's Q4 earnings report. Heading into the report, analysts ...